Bone Care International Receives Patent for Treating Prostate Cancer.MADISON, Wis.--(BUSINESS WIRE)--July 13, 1998--Bone Care International, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :BCII BCII Battle Command and Intelligence Integration ) today announced issuance by the United States Patent and Trademark Office The United States Patent and Trademark Office (PTO or USPTO) is an agency in the United States Department of Commerce that provides patent protection to inventors and businesses for their inventions, and trademark registration for product and intellectual property of patent 5,763,429 for treating prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. with vitamin D vitamin D Any of a group of fat-soluble alcohols important in calcium metabolism in animals to form strong bones and teeth and prevent rickets and osteoporosis. It is formed by ultraviolet radiation (sunlight) of sterols (see steroid) present in the skin. analogs. Several of the analogs under development by Bone Care are specifically claimed, as is the class of compounds with this structure. For the past year, Bone Care has been conducting clinical trials in patients with prostate cancer using one-alpha D2, a vitamin D analog. One-alpha D2 is the company's lead product in development for the treatment of secondary hyperparathyroidism secondary hyperparathyroidism Endocrinology ↑ Parathyroid activity with overproduction of PTH due to parathyroid hyperplasia in response to an extraparathyroid defect that results in ↓ Ca2+ Etiology Rickets, vitamin D deficiency, chronic renal failure associated with end stage renal disease. Encouraging results from the prostate cancer clinical trial were reported at the American Society of Clinical Oncology American Society of Clinical Oncology, or ASCO, is an organization that represents all clinical oncologists. Every year, ASCO holds a large symposium where physicians and researchers meet to convey and discuss research and ideas. meeting held in Los Angeles, CA in May 1998. The company's lead product in development for cancer treatment has potent antiproliferative effects on cancer cells in vitro and yet has five to thirty times lower toxicity than other available active vitamin D compounds. This would allow the company's compound to be used in higher dosages and with a greater safety margin. A United States patent application for treatment of colon cancer with this vitamin D analog has been allowed and will issue in August 1998. A patent application claiming compound coverage for this same analog has been allowed in Europe, and a patent is pending in the United States. Bone Care is an emerging pharmaceutical company which is developing D-hormone therapies with improved safety and efficacy profiles for treatment of (a) secondary hyperparathyroidism associated with end stage renal disease, pre-dialysis renal disease and osteoporosis, and (b) certain hyperproliferative diseases, including psoriasis and cancers of the breast, prostate and colon. EDITOR'S NOTE: In the second paragraph, in the phrase "one-alpha D2," the "2 "is a subscript.
CONTACT: Bone Care International, Madison
Dale W. Gutman, 608/236-2500
fax: 608/236-2525
|
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion